---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-25-000007"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2025-01-21T23:59:59+00:00"
generated_at: "2026-05-27T22:34:06.436021+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Inhibrx reports ozekibart Phase 1 CRC data: 40% ORR, median PFS 7.85 months

## Summary
- 1 CR, 3 PR among 10 evaluable patients; median PFS of 7.85 months.
- Durable disease control ≥180 days observed in 46.2% of treated patients.
- Grade ≥3 TEAEs in 30.8% of patients; most AEs mild to moderate.
- Expansion cohort enrolling up to 50 patients, data expected Q3 2025.
- Two PRs occurred in patients who had failed prior FOLFIRI-based therapy.

## SEC filing metadata
- accession: 0002007919-25-000007
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2025-01-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000007/0002007919-25-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000007/inhibrx-20250121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-25-000007
- JSON: https://secwatch.observer/filing/0002007919-25-000007.json
- Plain text: https://secwatch.observer/filing/0002007919-25-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.